completed

The objective of the VELETI II study was to evaluate the efficacy of stenting moderate SVG lesions with paclitaxel-eluting stents and/or PROMUS Element stent on reducing the first occurrence of the composite of cardiac death, myocardial infarction or repeat revascularization related to the target SVG over the duration of follow-up.

Primary Endpoint:

The first occurrence of the composite of cardiac death, myocardial infarction related to the target SVG or coronary revascularization related to the target SVG over the duration of the follow-up.

Jose Rodes-Cabau was the Principal Investigator.

Study Type

Interventional - Device

Study Design

Randomized, prospective, multicenter

NO. of Countries

1

NO. of Sites

16

NO. of Participants

125

Study Period

2011-2016

Sponsor

PHRI

Boston Scientific

Canadian Institutes of Health Research (CIHR)

PHRI internal grant

CANNeCTIN

Back To Top